Azilsartan reduced systolic blood pressure more effectively than other ARBs, with mean differences ranging from 3.0 to 4.8 mmHg compared to candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.
Meta-Analysis (n=13,945)
Does azilsartan improve systolic and diastolic blood pressure reduction compared to other ARBs in Japanese patients with hypertension?
Azilsartan demonstrated a more favorable efficacy profile in reducing office systolic and diastolic blood pressure compared to other ARBs in Japanese patients with hypertension.
Effect estimate: Mean difference 3.0 to 4.8 mmHg
Background:Angiotensin II receptor blockers (ARBs) are widely used for the management of hypertension in Japan; however, comparative efficacy data within the ARB drug class remain limited.
Nakajima et al. (Thu,) conducted a meta-analysis in Hypertension (n=13,945). Azilsartan vs. Other ARBs (candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan) was evaluated on Mean change in systolic blood pressure (SBP) from baseline in the office setting (Mean difference 3.0 to 4.8 mmHg). Azilsartan reduced systolic blood pressure more effectively than other ARBs, with mean differences ranging from 3.0 to 4.8 mmHg compared to candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: